// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Outcomes of a new inception cohort of patients with new rheumatoid arthritis (RA) receiving tight control in nurse-led clinics

Dawn Homer - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Multicentre survey of patient attitudes towards tapering of biologic drugs

Nour Ismail - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience

Benazir Saleem - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Rituximab biosimilar

Inflammatory conditions make up a larger proportion of the rheumatologist case load compared with 15 years ago: a district general hospital experience

Andrew Allard - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Rheumatology referrals: scope for improvement? Results from the Nottingham case-mix register

Aneesa Kapadia - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A multi-centre audit of secukinumab use and safety considerations in clinical practice

Roberta Rabbitts - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

secukinumab

Apparent high frequency of disease flare following switch from reference biologic rituximab (Mabthera) to a biosimilar (Truxima) in patients with vasculitis

Sarah Tansley - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Rituximab

Audit examining the difference in clinical outcomes amongst originator biologic treated patients with RA, PsA and AxSpA who were switched to biosimilar versions and monitored routinely at St George’s University Hospital NHS Trust

Saadia S Ali - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Infliximab

Eight years of a sustainable rheumatology patient participation group: lessons learnt in improving quality, safety and patient experience

Sarah Atkin - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Ethnic variation and infection rates in patients with rheumatological diagnoses on biologic therapy

Jo-Anne Strul - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Demographics and clinical characteristics of a national cohort of 280 patients with hypermobility syndrome and impact on their work disability

Mirjana Dojcinovska - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Anxiety, occupation and functional ability at the start of treatment and EULAR response are the main predictors of work outcomes in patients with rheumatoid arthritis commencing either methotrexate or biologics

James Gwinnutt - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

Methotrexate

Gout attack trajectories in a 3-year cohort study in primary care

Lorraine Watson - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

N/A

Switching to biosimilar rituximab: a real world study

Muhammad K Nisar - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

From zero to ten: difficulties in completing patient global assessment in rheumatoid arthritis: a mixed-methods study

Ricardo J O Ferreira - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Methotrexate and deprivation: an inconvenient truth

Sabreen Ali - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Social health profiles in primary care consulters for common musculoskeletal conditions: operationalisation of the PROMIS short form tool in patients with musculoskeletal conditions

Yousrah Uraiby - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Progression in ILD: comparison of rheumatological and non-rheumatological ILD

Shirish Dubey - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Quantifying care variation: the keystone of national quality improvement

Mark Yates - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Piloting an epidemiological study of the prevalence of Behçet’s disease in England

Priyanka Chandratre - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

N/A

Copyright © 2026. QuantiNova All rights reserved